Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens (Grand Rounds)
Credit(s): 1.00 (60 min)
August 17, 2022 12:00 - 1:00 PM ETAugust 24, 2022 12:00 - 1:00 PM ET November 4, 2022 12:15 - 1:15 PM ETNovember 15, 2022 12:00 - 1:00 PM ET
Physicians – AMA PRA Category 1 Credit(s) ™
Physicians/ABIM MOC – ABIM MOC Point(s)
Metastatic pancreatic cancer is a serious malignancy with limited treatment options and poor outcomes. It is also growing in incidence, and it is projected to be the second leading cause of cancer-related death before 2030. Treatment of pancreatic cancer relies primarily on chemotherapy, though targeted therapies are now available for the approximately 20% of patients who express actionable genetic alterations. Additionally, novel targeted therapies and immunotherapies are showing promise in early phase clinical trials, providing potential future treatment options for this deadly malignancy.
Selection between currently available treatment options and ongoing clinical trials relies heavily on biomarkers, as well as performance status, comorbidities, and patient preference. Communicating with patients regarding the importance of biomarker testing, treatment selection, and clinical trials is key to ensuring the best outcomes for patients with metastatic pancreatic cancer.
This activity, Metastatic Pancreatic Cancer: Staying Current with Approved and Emerging Evaluation and Treatment Regimens, will provide oncology clinicians with information on the most recent biomarkers and treatments for metastatic pancreatic cancer, expert recommendations for treatment selection and sequencing, and updated information on emerging biomarkers and targeted therapies for pancreatic cancer.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
This program is supported by educational grants from Bayer HealthCare Pharmaceuticals Inc. and Novartis Pharmaceuticals Corporation.
Clicking Start Activity indicates that you have reviewed the CME/CE information for this activity
CDK4/6 Inhibitors in the Real World: Evaluating the Evidence in HR-positive/HER2-negative Metastatic Breast Cancer (Grand Rounds)
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.